
    
      The primary objective of the study is:

      - decrease the accumulation of metabolites which can have a negative impact on neurological
      and systemic function of patients with SPG5.

      The secondary objectives of the study are:

        -  confirm the clinical and biological tolerance of the different candidate molecules under
           study

        -  improve the serum bile acid profile of patients with SPG5
    
  